FIELD: medicine.
SUBSTANCE: invention refers to biochemistry and represents versions of antibodies binding human anaplastic lymphoma kinase (ALK) protein. There are also presented: versions of radiolabelled or toxin antibodies; a DNA sequence coding the antibody, an expression vector containing the DNA sequence; a host cell transformed by the vector, a method for producing the antibody by cell cultivation, as well as using the antibody for preparing a drug for treating cancer or tumours.
EFFECT: invention may be effectively used for treating tumour or cancer.
32 cl, 5 dwg, 2 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RECOVERED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT (VERSIONS), METHOD OF TREATING hTNFα-MEDIATED DISEASES WITH MEDIATION THEREOF (VERSIONS), PHARMACEUTICAL COMPOSITION, RECOMBINANT HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT, RECOVERED NUCLEIC ACID (VERSIONS) | 2005 |
|
RU2458704C9 |
| ANTIBODIES TARGETING A RECEPTOR BOUND TO G-PROTEINS, AND METHODS FOR USE THEREOF | 2015 |
|
RU2725819C2 |
| ANTI-TUMOUR ANTIGEN ANTIBODY AND METHODS OF APPLICATION | 2011 |
|
RU2598711C2 |
| ANTIGEN ASSOCIATED WITH RHEUMATOID ARTHRITIS | 2013 |
|
RU2649368C2 |
| ANTIBODIES AGAINST PD-1 AND THEIR USE | 2018 |
|
RU2788616C2 |
| ISOLATED HUMAN ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT, ISOLATED NUCLEIC ACID (VARIANTS), RECOMBINANT EXPRESSION VECTOR, USING HOST-CELLS FOR EXPRESSION OF ANTIBODY AND METHOD FOR ITS SYNTHESIS, PHARMACEUTICAL COMPOSITION AND METHOD FOR INHIBITION OF ACTIVITY OF HUMAN TNFα | 1997 |
|
RU2268266C2 |
| METHOD OF DESTROYING CELLS USING EFFECTOR FUNCTIONS OF ANTI-EphA4 ANTIBODIES | 2007 |
|
RU2429246C2 |
| ANTIBODIES AGAINST A5 REPRESENTATIVE OF 19 FAMILY WITH SIMILARITY OF SEQUENCES AND THEIR APPLICATION METHOD | 2019 |
|
RU2785436C2 |
| HUMAN IL-13 ANTIBODY MOLECULES | 2004 |
|
RU2387667C2 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF | 2016 |
|
RU2648152C2 |
